UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 21, 2007
Opexa Therapeutics, Inc.
------------------------
(Exact Name of Registrant as Specified in Its Charter)
Texas
-----
(State or Other Jurisdiction of Incorporation)
001-33004 76-0333165
--------- ----------
(Commission File Number) (I.R.S. Employer Identification No.)
2635 N. Crescent Ridge Drive
The Woodlands, Texas 77381
-------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (281) 272-9331
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On June 21, 2007, Registrant reported positive top-line data from its open-label
Phase I/II extension clinical trial of the investigational T-cell vaccine,
Tovaxin(TM), for multiple sclerosis. A copy of the press release is attached as
Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(c) Exhibit 99.1
The following exhibit is to be filed as part of this 8-K:
Exhibit No. Description
- ----------- -----------
99.1 Press release issued June 21, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OPEXA THERAPEUTICS, INC.
By: /s/ David B. McWilliams
----------------------------------------
David B. McWilliams, Chief Executive
Officer
DATE: June 21, 2007
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release issued June 21, 2007